UK government plans to hike revenue clawback rates beginning in April
Ignoring warning calls from pharma companies and the Association of the British Pharmaceutical Industry (ABPI), the UK government announced it’s planning to raise the revenue clawback rate paid by pharmaceutical companies on the Statutory Scheme for Branded Medicines from 24.4% to 27.5%. The higher rates are proposed to kick in on April 1.
The Statutory Scheme, which is governed under UK law, is one of two that companies can use. The Voluntary Scheme for Branded Medicines Pricing and Access is the second option, and typically has lower rates and is negotiated between the government and pharmas. It’s a longstanding agreement between the government and industry to keep medicines affordable for the National Health Service (NHS). A hike is also under consideration for the voluntary scheme.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.